<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02423122</url>
  </required_header>
  <id_info>
    <org_study_id>EIP-VX00-745-302</org_study_id>
    <nct_id>NCT02423122</nct_id>
  </id_info>
  <brief_title>A PET Study of the Effects of p38 MAP Kinase Inhibitor, VX-745, on Amyloid Plaque Load in Alzheimer's Disease (AD)</brief_title>
  <official_title>A Clinical Study of Two Doses of a Selective p38 MAP Kinase Inhibitor, VX-745, to Evaluate the Effects of 12-Week Oral Twice-Daily Dosing on Amyloid Plaque Load as Assessed by Quantitative Dynamic 11C-PiB Positive Emission Tomography (PET) Amyloid Scanning</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>EIP Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>EIP Pharma Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess the effects of administration of VX-745 for 12 weeks on amyloid plaque
      burden in Alzheimer's disease (AD). Subjects who meet entry criteria will undergo 11C-PiB
      (Carbon-11-labeled Pittsburgh Compound B) positron emission tomography (PET) at baseline and
      after 45 days of dosing with VX-745. Cognitive testing will also be conducted at baseline and
      day 45.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2015</start_date>
  <completion_date type="Actual">September 2016</completion_date>
  <primary_completion_date type="Actual">July 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Change From Baseline in Amyloid Plaque Burden by 11C-PiB PET</measure>
    <time_frame>Baseline compared to following 12 weeks' dosing with VX-745</time_frame>
    <description>Percent change in global cortical amyloid specific PET signal (BPND)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of 11C-PiB Responders</measure>
    <time_frame>Day 84</time_frame>
    <description>Number of patients meeting protocol pre-specified definition of response: &gt; 7% reduction in global cortical BPND</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Wechsler Memory Scale (WMS) Immediate Recall Composite</measure>
    <time_frame>Baseline to Day 84</time_frame>
    <description>WMS immediate-recall composite score consisted of the sum of the scores on Logical Memory I, Verbal Paired Associates I, and Visual Reproduction I. The composite score ranges from 0 to 136; with higher score indicating better performance.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Wechsler Memory Scale (WMS) Delayed Recall Composite</measure>
    <time_frame>Change from baseline to Day 84</time_frame>
    <description>WMS delayed-recall composite score at each testing sessions consisted of the sum of the scores on Logical Memory II, Verbal Paired Associates II, and Visual Reproduction II. The composite score ranges from 0 to 136; with higher scores indicating better performance.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Alzheimer's Disease</condition>
  <condition>Mild Cognitive Impairment</condition>
  <arm_group>
    <arm_group_label>VX-745 dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Active Group 1: VX-745 40 mg twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VX-745 dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Active Group 2: VX-745 125 mg twice daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VX-745</intervention_name>
    <description>Orally-Active Selective P45 MAP Kinase inhibitor</description>
    <arm_group_label>VX-745 dose 1</arm_group_label>
    <arm_group_label>VX-745 dose 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Willing and able to provide informed consent

          -  Diagnosis of mild cognitive impairment (MCI) due to probable AD or of mild AD

          -  MMSE range: 20 to 28

          -  Evidence of amyloid pathology by amyloid PET scan

          -  Participants may be taking medications for AD, provided that the dose of these
             medications has been stable for &gt;3 months

          -  Proficiency in Dutch and adequate visual and auditory abilities to be able to perform
             all aspects of the cognitive and functional tests

          -  Adequate visual and auditory abilities to perform all aspects of the cognitive and
             functional assessments.

        Exclusion Criteria:

          -  Evidence of neurodegenerative disease other than AD

          -  Inability for any reason to undergo PET and fMRI scans (including notably: history of
             allergic reaction of any severity to 11C-PiB injection; pacemaker, vascular stent or
             stent graft)

          -  Psychiatric disorder that would compromise ability to comply with study requirements

          -  Significant cardiovascular, pulmonary, renal, liver, infectious disease, immune
             disorder or metabolic/endocrine disorders or other disease that would preclude
             treatment with p38 MAP kinase inhibitor and/or assessment of drug safety and efficacy

          -  Recent (&lt;90 days) changes to AD medications prescribed for cognitive reasons or with
             the potential to impact cognition

          -  Participation in a study of an investigational drug less than 6 months or 5 half-lives
             of the investigational drug, whichever is longer, before enrollment in the study

          -  Male subjects with female partner of child-bearing potential who are unwilling or
             unable to adhere to contraception requirements

          -  Female subjects who have not reached menopause or have not had a hysterectomy or
             bilateral oophorectomy/salpingoophorectomy

          -  Positive urine or serum pregnancy test or plans desires to become pregnant during the
             course of the trial

          -  Any factor deemed by the investigator to be likely to interfere with study conduction
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philip Scheltens, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Alheimer Research Center, VU medisch centrum</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Alzheimer Research Center, VU Medical Center</name>
      <address>
        <city>Amsterdam</city>
        <zip>1081 HV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <study_first_submitted>April 14, 2015</study_first_submitted>
  <study_first_submitted_qc>April 17, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 22, 2015</study_first_posted>
  <results_first_submitted>January 4, 2018</results_first_submitted>
  <results_first_submitted_qc>March 13, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">June 14, 2019</results_first_posted>
  <last_update_submitted>March 13, 2019</last_update_submitted>
  <last_update_submitted_qc>March 13, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 14, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Plaque, Amyloid</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Neflamapimod (VX-745) Dose 1</title>
          <description>Active Group 1: VX-745 40 mg twice daily
VX-745: Orally-Active Selective P45 MAP Kinase inhibitor</description>
        </group>
        <group group_id="P2">
          <title>Neflamapimod (VX-745) Dose 2</title>
          <description>Active Group 2: VX-745 125 mg twice daily
VX-745: Orally-Active Selective P45 MAP Kinase inhibitor</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Neflamapimod (VX-745) Dose 1</title>
          <description>Active Group 1: VX-745 40 mg twice daily
VX-745: Orally-Active Selective P45 MAP Kinase inhibitor</description>
        </group>
        <group group_id="B2">
          <title>Neflamapimod (VX-745) Dose 2</title>
          <description>Active Group 2: VX-745 125 mg twice daily
VX-745: Orally-Active Selective P45 MAP Kinase inhibitor</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="9"/>
            <count group_id="B2" value="7"/>
            <count group_id="B3" value="16"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68" lower_limit="60" upper_limit="76"/>
                    <measurement group_id="B2" value="65" lower_limit="60" upper_limit="75"/>
                    <measurement group_id="B3" value="66.5" lower_limit="60" upper_limit="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Netherlands</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent Change From Baseline in Amyloid Plaque Burden by 11C-PiB PET</title>
        <description>Percent change in global cortical amyloid specific PET signal (BPND)</description>
        <time_frame>Baseline compared to following 12 weeks' dosing with VX-745</time_frame>
        <population>All patients with baseline and Day 84 11C-PiB scan. One patient in 40 mg dose group could not cooperate for Day 84 PET scan due to having developed MRI-induced panic attack.</population>
        <group_list>
          <group group_id="O1">
            <title>Neflamapimod (VX-745) Dose 1</title>
            <description>Active Group 1: VX-745 40 mg twice daily
VX-745: Orally-Active Selective P45 MAP Kinase inhibitor</description>
          </group>
          <group group_id="O2">
            <title>Neflamapimod (VX-745) Dose 2</title>
            <description>Active Group 2: VX-745 125 mg twice daily
VX-745: Orally-Active Selective P45 MAP Kinase inhibitor</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Amyloid Plaque Burden by 11C-PiB PET</title>
          <description>Percent change in global cortical amyloid specific PET signal (BPND)</description>
          <population>All patients with baseline and Day 84 11C-PiB scan. One patient in 40 mg dose group could not cooperate for Day 84 PET scan due to having developed MRI-induced panic attack.</population>
          <units>percentage change from baseline</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.57" lower_limit="-11.65" upper_limit="4.83"/>
                    <measurement group_id="O2" value="4.57" lower_limit="0.56" upper_limit="12.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of 11C-PiB Responders</title>
        <description>Number of patients meeting protocol pre-specified definition of response: &gt; 7% reduction in global cortical BPND</description>
        <time_frame>Day 84</time_frame>
        <population>All patients with baseline and Day 84 11C-PiB scan. One patient in 40 mg dose group could not cooperate for Day 84 PET scan due to having developed MRI-induced panic attack.</population>
        <group_list>
          <group group_id="O1">
            <title>Neflamapimod (VX-745) Dose 1</title>
            <description>Active Group 1: VX-745 40 mg twice daily
VX-745: Orally-Active Selective P45 MAP Kinase inhibitor</description>
          </group>
          <group group_id="O2">
            <title>Neflamapimod (VX-745) Dose 2</title>
            <description>Active Group 2: VX-745 125 mg twice daily
VX-745: Orally-Active Selective P45 MAP Kinase inhibitor</description>
          </group>
        </group_list>
        <measure>
          <title>Number of 11C-PiB Responders</title>
          <description>Number of patients meeting protocol pre-specified definition of response: &gt; 7% reduction in global cortical BPND</description>
          <population>All patients with baseline and Day 84 11C-PiB scan. One patient in 40 mg dose group could not cooperate for Day 84 PET scan due to having developed MRI-induced panic attack.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Wechsler Memory Scale (WMS) Immediate Recall Composite</title>
        <description>WMS immediate-recall composite score consisted of the sum of the scores on Logical Memory I, Verbal Paired Associates I, and Visual Reproduction I. The composite score ranges from 0 to 136; with higher score indicating better performance.</description>
        <time_frame>Baseline to Day 84</time_frame>
        <population>All patients with baseline and day 84 WMS testing data. One subject in 40 mg dose group did not complete the Day 84 WMS assessment after having developed MRI-induced panic attack.</population>
        <group_list>
          <group group_id="O1">
            <title>Neflamapimod (VX-745) Dose 1</title>
            <description>Active Group 1: VX-745 40 mg twice daily
VX-745: Orally-Active Selective P45 MAP Kinase inhibitor</description>
          </group>
          <group group_id="O2">
            <title>Neflamapimod (VX-745) Dose 2</title>
            <description>Active Group 2: VX-745 125 mg twice daily
VX-745: Orally-Active Selective P45 MAP Kinase inhibitor</description>
          </group>
        </group_list>
        <measure>
          <title>Wechsler Memory Scale (WMS) Immediate Recall Composite</title>
          <description>WMS immediate-recall composite score consisted of the sum of the scores on Logical Memory I, Verbal Paired Associates I, and Visual Reproduction I. The composite score ranges from 0 to 136; with higher score indicating better performance.</description>
          <population>All patients with baseline and day 84 WMS testing data. One subject in 40 mg dose group did not complete the Day 84 WMS assessment after having developed MRI-induced panic attack.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.0" spread="11.0"/>
                    <measurement group_id="O2" value="13.4" spread="12.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Wechsler Memory Scale (WMS) Delayed Recall Composite</title>
        <description>WMS delayed-recall composite score at each testing sessions consisted of the sum of the scores on Logical Memory II, Verbal Paired Associates II, and Visual Reproduction II. The composite score ranges from 0 to 136; with higher scores indicating better performance.</description>
        <time_frame>Change from baseline to Day 84</time_frame>
        <population>All patients with baseline and day 84 WMS testing data. One subject in 40 mg dose group did not complete the Day 84 WMS assessment after having developed MRI-induced panic attack.</population>
        <group_list>
          <group group_id="O1">
            <title>Neflamapimod (VX-745) Dose 1</title>
            <description>Active Group 1: VX-745 40 mg twice daily
VX-745: Orally-Active Selective P45 MAP Kinase inhibitor</description>
          </group>
          <group group_id="O2">
            <title>Neflamapimod (VX-745) Dose 2</title>
            <description>Active Group 2: VX-745 125 mg twice daily
VX-745: Orally-Active Selective P45 MAP Kinase inhibitor</description>
          </group>
        </group_list>
        <measure>
          <title>Wechsler Memory Scale (WMS) Delayed Recall Composite</title>
          <description>WMS delayed-recall composite score at each testing sessions consisted of the sum of the scores on Logical Memory II, Verbal Paired Associates II, and Visual Reproduction II. The composite score ranges from 0 to 136; with higher scores indicating better performance.</description>
          <population>All patients with baseline and day 84 WMS testing data. One subject in 40 mg dose group did not complete the Day 84 WMS assessment after having developed MRI-induced panic attack.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.5" spread="7.0"/>
                    <measurement group_id="O2" value="10.4" spread="11.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>40 mg Dose Group</title>
        </group>
        <group group_id="E2">
          <title>125 mg Dose Group</title>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>John Alam</name_or_title>
      <organization>EIP Pharma</organization>
      <email>jalam@eippharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

